biostudies-literatureFreiwan MTempus Public FoundationNational Research, Development and Innovation OfficeHungarian Academy of SciencesCancer Foundation Finland srMinistry of Human Capacities2201https://www.ebi.ac.uk/biostudies/studies/S-EPMC8877618biostudies-literatureUnknown23(4)Despite the effectiveness of doxorubicin (DOXO) as a chemotherapeutic agent, dose-dependent development of chronic cardiotoxicity limits its application. The angiotensin-II receptor blocker losartan is commonly used to treat cardiac remodeling of various etiologies. The beta-3 adrenergic receptor agonist mirabegron was reported to improve chronic heart failure. Here we investigated the effects of losartan, mirabegron and their combination on the development of DOXO-induced chronic cardiotoxicity. Male Wistar rats were divided into five groups: (i) control; (ii) DOXO-only; (iii) losartan-treated DOXO; (iv) mirabegron-treated DOXO; (v) losartan plus mirabegron-treated DOXO groups. The treatments started 5 weeks after DOXO administration. At week 8, echocardiography was performed. At week 9, International journal of molecular sciencesInvestigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.PMC887761820391-3/2018/FEKUSTRATNKFIH FK129094EFOP-3.6.3-VEKOP-16-2017-00009Stipendium Hungaricum ScholarshipTKP2021-EGA-32Stipendium Hungaricum Program220015GINOP-2.3.2-15-2016-00040ÚNKP-21-3-SZTE-97 to M.G.K., ÚNKP-21-3-SZTE-98 to Z.Z.A.K., and ÚNKP-20-5-SZTE-166 to M.SJános Bolyai Research FellowshipLosonczi RFoldesi ISarkozy MDinh HDux LKovacs MGKovacs FKovacs ZZAHorvath PSiska ACserni GSzucs GKriston ACsont TFreiwan MfalseInvestigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.Despite the effectiveness of doxorubicin (DOXO) as a chemotherapeutic agent, dose-dependent development of chronic cardiotoxicity limits its application. The angiotensin-II receptor blocker losartan is commonly used to treat cardiac remodeling of various etiologies. The beta-3 adrenergic receptor agonist mirabegron was reported to improve chronic heart failure. Here we investigated the effects of losartan, mirabegron and their combination on the development of DOXO-induced chronic cardiotoxicity. Male Wistar rats were divided into five groups: (i) control; (ii) DOXO-only; (iii) losartan-treated DOXO; (iv) mirabegron-treated DOXO; (v) losartan plus mirabegron-treated DOXO groups. The treatments started 5 weeks after DOXO administration. At week 8, echocardiography was performed. At week 9, 2022-01-01T00:00:00Z2022 Feb2026-04-08T17:27:39.546Z2025-04-19T22:38:49.513ZS-EPMC88776183521631710.3390/ijms23042201